Pharmafile Logo
Pharmafocus logo
Advanced Search

UCB

Showing 15 posts of 76 posts found.

FDA accepts UCB’s sBLA for Bimzelx

April 5, 2024
Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA

UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application …

News

Microsoft and UCB collaborate to treat immunological and neurological diseases

February 23, 2021
Manufacturing and Production Microsoft, UCB, artificial intelligence

UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining UCB’s drug discovery and development …

News
shutter

UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+

July 30, 2020
Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership

UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …

News

UCB’s investigational IL-17A and IL-17F inhibitor outclasses Novartis’ Cosentyx in plaque psoriasis

July 24, 2020
Medical Communications, Research and Development Cosentyx, UCB, pharma, psoriasis

UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …

News

UCB to invest £1 billion into UK R&D

December 6, 2018
Manufacturing and Production, Research and Development R&D, UCB, UK, brussels, investment, research

The Brussels-based multinational UCB will invest £1 billion into UK research and development, according to the government’s Life Sciences Sector …

News

NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis

December 4, 2018
Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis

UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …

News
shutterstock_292920209

UCB and Biogen’s lupus drug falls short at Phase 2b

October 24, 2018
Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …

News

Working Life: Jean-Christophe Tellier, CEO of UCB Pharma

September 24, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB, Working Life, feature

Just as his company announced robust H1 2018 financials, UCB’s Jean-Christophe Tellier spoke to Pharmafocus to share his experiences of …

Feature
top_10_image

Top Ten most popular articles on Pharmafile.com this week

September 21, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Novartis, Novo Nordisk, Senate, UCB, manufacturing, opioid crisis, top 10

Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move …

News

UCB brings promising plaque psoriasis data to EADV 2018

September 14, 2018
Medical Communications, Research and Development EADV 2018, UCB, pharma, psoriasis

UCB has joined in on the wave of new psoriasis data emerging from the European Academy of Dermatology and Venereology …

News

EMA approves Cimzia for use in treating plaque psoriasis

July 2, 2018
Sales and Marketing Cimzia, EMA, UCB, indication, pharmaceutical

The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia …

News

UCB’s Cimzia secures first-of-its-kind FDA approval in plaque psoriasis

May 29, 2018
Manufacturing and Production, Sales and Marketing Cimzia, FDA, UCB, US, pharma, psoriasis

The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …

News

FDA refuses approval of Amgen osteoporosis drug

July 17, 2017
Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical

Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …

News
ucb_logo_pole2

US court rules in favour of UCB in patent dispute, shares jump

August 16, 2016
Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat

UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …

News

Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis

July 13, 2016
Research and Development, Sales and Marketing Cimzia, NICE, UCB, regulation, rheumatoid arthritis

The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or …

News

Latest content

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024

ANGLE signs commercial agreement with AstraZeneca

April 26, 2024

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024